HomeAI · summaries
Storia in 8 fonti
Eli Lilly's obesity drug shows promise in treating sleep apnea
Eli Lilly's retatrutide significantly reduces sleep apnea severity, knee osteoarthritis pain, and promotes substantial weight loss in adults with obesity, trial results reveal.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options,…
- ·
morningstar.com
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea,…
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential…
